Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zandelisib + Venetoclax + Rituximab in R/R CLL (CORAL)
NCT05209308Phase 2Withdrawn
- Sponsor
- MEI Pharma
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zandelisib in chronic lymphocytic leukemia (CLL), sponsored by MEI Pharma. Planned start Nov 2022; status: withdrawn.
02
Drugs
zandelisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05209308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209308.